Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

被引：20

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Derkach, Andriy ^{[2
]}

Gowda, Lohith ^{[1
]}

Menghrajani, Kamal ^{[3
,4
]}

DeWolf, Susan ^{[3
]}

Ruiz, Josel D. ^{[5
]}

Ponce, Doris M. ^{[4
,5
]}

Shaffer, Brian C. ^{[4
,5
]}

Tamari, Roni ^{[4
,5
]}

Young, James W. ^{[4
,5
,6
]}

Jakubowski, Ann A. ^{[4
,5
]}

Gyurkocza, Boglarka ^{[4
,5
]}

Chan, Alexander ^{[7
]}

Xiao, Wenbin ^{[7
]}

Glass, Jacob ^{[3
,4
]}

King, Amber C. ^{[8
]}

Cai, Sheng F. ^{[3
,4
]}

Daniyan, Anthony ^{[3
,4
]}

Famulare, Christopher ^{[3
]}

Cuello, Bernadette M. ^{[3
]}

Podoltsev, Nikolai A. ^{[1
]}

Roshal, Mikhail ^{[7
]}

Giralt, Sergio ^{[4
,5
]}

Perales, Miguel-Angel ^{[4
,5
]}

Seropian, Stuart ^{[1
]}

Cho, Christina ^{[4
,5
]}

Zeidan, Amer M. ^{[1
]}

Prebet, Thomas ^{[1
]}

Stein, Eytan M. ^{[3
,4
]}

Tallman, Martin S. ^{[3
,4
]}

Goldberg, Aaron D. ^{[3
,4
]}

Stahl, Maximilian ^{[3
,4
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA

[6] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pharm, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 14期

基金：

美国国家卫生研究院;

关键词：

Acute myeloid leukemia; AML; MDS; venetoclax; transplant; RELAPSE;

D O I：

10.1080/10428194.2021.1966788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.

引用

页码：3394 / 3401

页数：8

共 50 条

[31] Intravenous Compared to Oral Busulfan with Cyclophophamide for Allogeneic Hematopoietic Progenitor Cell Transplant Conditioning for AML and MDS
Sobecks, Ronald
Rybicki, Lisa
Kalaycio, Matt
Dean, Robert
Andresen, Steven
Pohlman, Brad
Bolwell, Brian J.
Copelan, Edward A.
BLOOD, 2010, 116 (21) : 1427 - 1428
[32] The Management of Relapsed AML or MDS Following a T-Cell Depleted Allogeneic Stem Cell Transplant
Morawa, Ewelina
Zabor, Emily
Maloy, Molly
Devlin, Sean
Giralt, Sergio A.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S300 - S300
[33] Different Incidence and Implications of DNA Hypermethylation in De Novo AML Compared to High-Risk MDS and AML Following MDS
Deneberg, Stefan
Groevdall, Michael
Jansson, Monika
Gaidzik, Verena I.
Corbacioglu, Andrea
Nahi, Hareth
Bengtzen, Sofia
Doehner, Konstanze
Paul, Christer
Hellstroem-Lindberg, Eva
Lehmann, Soeren
BLOOD, 2008, 112 (11) : 1146 - 1147
[34] AML relapse following allogeneic hematopoietic stem cell transplant: a single center experience
Akpoguma, Andrea O.
Grobe, Connie
Mott, Sarah C.
De Magalhaes-Silverman, Margarida
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[35] Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas
王强力
ChinaMedicalAbstracts(InternalMedicine), 2017, 34 (01) : 54 - 55
[36] Feasibility and results of prophylactic donor lymphocyte transfusion following allogeneic stem cell transplantation with reduced-conditioning for high-risk AML and MDS
Schleuning, M
Schmid, C
Ledderose, G
Tischer, J
Baurmann, H
Schwerdtfeger, R
Kolb, HJ
BONE MARROW TRANSPLANTATION, 2005, 35 : S79 - S79
[37] Durable remission after prophylactic donor lymphocyte transfusion following allogeneic stem cell transplantation with reduced conditioning for high-risk AML and MDS
Schleuning, M
Schmid, C
Ledderose, G
Tischer, J
Humann, M
Ullmann, J
Schwerdtfeger, R
Kolb, HJ
BLOOD, 2004, 104 (11) : 89A - 89A
[38] Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients
Baronciani, Donatella
Rambaldi, Alessandro
Iori, Anna Paola
Di Bartolomeo, Paolo
Pilo, Federica
Pettinau, Martina
Depau, Cristina
Mico, Caterina
Santarone, Stella
Angelucci, Emanuele
AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (09) : 717 - 720
[39] Favorable outcomes in elderly and high-risk patients with AML and MDS following T-cell depleted reduced intensity conditioned allogeneic stem cell transplantation
Nicholson, E.
Mackinnon, S.
Thomson, K. J.
Sudak, J.
Fielding, A. K.
Kottaridis, P.
Peggs, K. S.
Morris, E. C.
Chakraverty, R.
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 3 - 3
[40] FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION
Nicholson, E.
Mackinnon, S.
Thomson, K. J.
Sudak, J.
Fielding, A. K.
Kottaridis, P.
Peggs, K. S.
Morris, E. C.
Chakraverty, R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S346 - S347

← 1 2 3 4 5 →